ArticleAnnals of translational medicine2020
Pathological myopia-induced antioxidative proteins in the vitreous humor.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Systematic review and meta-analysis of mass spectrometry proteomics applied to ocular fluids to assess potential biomarkers of age-related macular degeneration.BMC ophthalmology · 2023Pooled it
- Choroidal Thickness and Its Association With Age, Axial Length, and Refractive Error in Chinese Adults.Investigative ophthalmology & visual science · 2022Pooled it
- Plasma Metabolic Profile with Machine Learning Reveals Distinct Diagnostic and Biological Signatures for Pathologic Myopia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Key role for inflammation-related signaling in the pathogenesis of myopia based on evidence from proteomics analysis.Scientific reports · 2024Article
- Unmasking of molecular players: proteomic profiling of vitreous humor in pathologic myopia.BMC ophthalmology · 2024Observational
- Article
- Vitreous metabolomic signatures of pathological myopia with complications.Eye (London, England) · 2023Article
- Retinal Proteome Analysis Reveals a Region-Specific Change in the Rabbit Myopia Model.International journal of molecular sciences · 2023Article
- Circulating Vitreous microRNA as Possible Biomarker in High Myopic Eyes with Macular Hole.International journal of molecular sciences · 2022Article
- Aqueous humor proteomic analysis of acute angle-closure glaucoma with visual field loss.Annals of translational medicine · 2021Article
- IMI 2021 Yearly Digest.Investigative ophthalmology & visual science · 2021Review
- Lipid Peroxidation in Subretinal Fluid: Some Light on the Prognosis Factors.Biomolecules · 2021Article
- Omics in Myopia.Journal of clinical medicine · 2020Review
- Animal modeling for myopia.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate differentially expressed proteins in the vitreous humor (VH) of pathological myopia (PM) and normal eyes.
methodsVH samples were collected from patients undergoing surgical treatment for rhegmatogenous retinal detachment (RRD), idiopathic epiretinal membrane (ERM), myopic retinoschisis (MRS) or macular hole (MH). A label-free quantitative proteomic analysis was performed to detect the differentially expressed proteins, and expression of three differentially expressed proteins was confirmed by ELISA.
resultsIn PM patients (MH-PM, MRS-PM and RRD-PM), the expression of prostaglandin-H2 D-isomerase (PGDS) and glutathione peroxidase 3 (GPX3) was significantly lower than in controls (MH, ERM, and RRD). The versican core protein expression decreased in the PM group. The vitreous concentrations of PGDS and GPX3 in patients with axial length (AL) of 26.5-29.0 mm were higher than in patients with AL >29.0 mm or AL <26.5 mm. NRF-2 expression was the lowest in patients with AL >29.0 mm.
conclusionsOur study provides new evidence on the molecular changes in the VH of PM patients, and these molecules have the potential to become new targets for the therapy of PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.